Fig. 3.

Guanosine increases β-catenin immunocontent in the hippocampus and PFC. Timeline of the experimental protocol (a). β-catenin immunocontent in the cytosolic fraction in the hippocampus (t₍₁₀₎ = 0.76, p = 0.46) (b) and PFC [t₍₁₀₎ = − 2.04, p = 0.06) (c). Effect of the treatment with guanosine in immunocontent of β-catenin in nuclear fraction in hippocampus (t₍₁₀₎ = − 3.99, p < 0.05) (d) and PFC (t₍₁₀₎ = 3.31, p < 0.05) (e). Results are presented as percentual of control (considered 100%) and are expressed as mean + S.E.M. (n = 6). *p < 0.05; guanosine-treated group compared with the vehicle-treated group